



For further information:
Marta Campos Martínez
mcampos@rovi.es
Tel: +34 91 244 44 22

ROVI implements Strategic Pharmaceutical Manufacturing and Marketing Agreement in Spain

Madrid, 26 March 2010 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI or the “Company”) announces as of today the implementation of the strategic pharmaceutical agreement for marketing and manufacturing reached by ROVI and Merck Sharp & Dohme (MSD) in Spain on 23 July 2009, which was stated the following day 24 July 2009 as a Relevant Fact to the Comisión Nacional del Mercado de Valores.

The implementation of this strategic pharmaceutical agreement implies the transfer of the manufacturing and packaging plan at Alcalá de Henares, Frosst Ibérica, to ROVI Imaging, S.L., a subsidiary of Laboratorios Farmacéuticos Rovi, S.A. (ROVI), and the entry into force, with effect from 31 March 2010, of the main agreements reached on 23 July 2009. These agreements include: (i) the manufacturing by ROVI of the pharmaceutical products of MSD that are currently produced at the plant, and their packaging for worldwide supply for a period of five years, and packaging for Spain for a period of seven years, and (ii) the granting of distribution rights in Spain, in a co-marketing regime, for five products of MSD, which can be exercised for the next 10 years.

In addition, as of 23 July 2009, ROVI incorporated into its marketing portfolio two MSD products for sale in Spain, Tryptizol™ (amitriptyline) and Ameride™ (amiloride & hydrochlorothiazide), and from 1 January 2010, Prinivil® and Prinivil® Plus have completed the MSD products incorporated by ROVI.



All these actions have been implemented in accordance with the terms of the agreement reached on 23 July 2009, with no major deviation from these terms which needs to be noted.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said: “we are very satisfied by the implementation of this transaction, which will serve to generate new sources of revenues for ROVI, by strengthening two important growth drivers of the company, the toll manufacturing area and the pharmaceutical specialty area. As we said before, we believe that the extensive experience and capacity of MSD to launch innovative products, combined with the efforts of our sales team, will ensure the sustained growth of the pharmaceutical specialty business. In addition, our interest in diversifying the toll manufacturing area provides us with an opportunity for long term growth, as it allows the potential of the infrastructure we have acquired to be maximised.”

About the Alcalá facility

The plant in Alcalá, FROSST IBÉRICA, has a surface area of 83,000 m², and has a long tradition of manufacturing excellence in pharmaceutical products. With the acquisition, ROVI will diversify its toll manufacturing business by incorporating state of the art technology – roller compaction - for manufacturing oral formulations. This technology broadens ROVI’s current services, which today include toll manufacturing of the aseptic filling of pre-filled syringes and terminal sterilisation.

About ROVI

ROVI is a fully integrated, profitable Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 27 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, bemiparin. ROVI’s research and development pipeline is focused primarily on addressing currently unmet medical needs by



developing new LMWH-based products and expanding applications for its existing LMWH-based products. ROVI manufactures the active biological ingredient (bemiparin) for its principal proprietary product and product candidates and the injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. For more information, visit <http://www.rovi.es>.